|
TM6SF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.7150000025955E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.17220000372953E-08 |
| Normal-vs-Stage2 |
8.848400E-01 |
| Normal-vs-Stage3 |
2.84369999770107E-08 |
| Normal-vs-Stage4 |
7.25659976552606E-10 |
| Stage1-vs-Stage2 |
7.424200E-02 |
| Stage1-vs-Stage3 |
3.101600E-01 |
| Stage1-vs-Stage4 |
1.317570E-02 |
| Stage2-vs-Stage3 |
3.669900E-02 |
| Stage2-vs-Stage4 |
5.540100E-03 |
| Stage3-vs-Stage4 |
1.202610E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.04140054754976E-10 |
| Normal-vs-AfricanAmerican |
7.343800E-02 |
| Normal-vs-Asian |
2.5341999998485E-07 |
| Caucasian-vs-AfricanAmerican |
3.914000E-01 |
| Caucasian-vs-Asian |
5.331400E-01 |
| AfricanAmerican-vs-Asian |
2.878000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.5267999998776E-07 |
| Normal-vs-Female |
1.72199999814993E-08 |
| Male-vs-Female |
7.311600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.24900001031403E-09 |
| Normal-vs-Age(41-60Yrs) |
1.46620000029962E-07 |
| Normal-vs-Age(61-80Yrs) |
5.123500E-03 |
| Normal-vs-Age(81-100Yrs) |
1.464010E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.479600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.274170E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.272000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.823010E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.140800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.740000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.862200E-02 |
| Classical-VS-Follicular |
8.70590000090488E-08 |
| Classical-VS-Other |
6.420200E-01 |
| Classical-VS-Normal |
7.76356756659879E-12 |
| Tall-VS-Follicular |
6.83250001021207E-09 |
| Tall-VS-Other |
1.217430E-01 |
| Tall-VS-Normal |
4.89399631931065E-11 |
| Follicular-VS-Other |
1.679410E-01 |
| Follicular-VS-Normal |
5.477200E-01 |
| Other-VS-Normal |
1.539570E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.303600E-03 |
| Normal-vs-N1 |
3.33066907387547E-16 |
| N0-vs-N1 |
1.7727999956918E-08 |
|
|
